Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 60
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Circ Res ; 134(9): 1083-1097, 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38662860

ABSTRACT

Poor air quality accounts for more than 9 million deaths a year globally according to recent estimates. A large portion of these deaths are attributable to cardiovascular causes, with evidence indicating that air pollution may also play an important role in the genesis of key cardiometabolic risk factors. Air pollution is not experienced in isolation but is part of a complex system, influenced by a host of other external environmental exposures, and interacting with intrinsic biologic factors and susceptibility to ultimately determine cardiovascular and metabolic outcomes. Given that the same fossil fuel emission sources that cause climate change also result in air pollution, there is a need for robust approaches that can not only limit climate change but also eliminate air pollution health effects, with an emphasis of protecting the most susceptible but also targeting interventions at the most vulnerable populations. In this review, we summarize the current state of epidemiologic and mechanistic evidence underpinning the association of air pollution with cardiometabolic disease and how complex interactions with other exposures and individual characteristics may modify these associations. We identify gaps in the current literature and suggest emerging approaches for policy makers to holistically approach cardiometabolic health risk and impact assessment.


Subject(s)
Air Pollution , Cardiovascular Diseases , Environmental Exposure , Humans , Air Pollution/adverse effects , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Environmental Exposure/adverse effects , Air Pollutants/adverse effects , Cardiometabolic Risk Factors , Exposome , Metabolic Diseases/epidemiology , Metabolic Diseases/metabolism , Metabolic Diseases/etiology , Particulate Matter/adverse effects
2.
Curr Med Res Opin ; 39(1): 19-25, 2023 01.
Article in English | MEDLINE | ID: mdl-36189747

ABSTRACT

OBJECTIVE: To explore the distribution law of traditional Chinese medicine (TCM) syndrome types in patients with psoriasis vulgaris complicated by metabolic disorders based on the same pathogenic factors as blood-heat and blood-stasis in the pathogenesis of psoriasis and metabolic disorders and to further analyze the correlation between adiponectin and the distribution law. METHODS: From 1 January 2018 to 31 December 2019, patients diagnosed with psoriasis in the inpatient or outpatient department of Dermatology Ward of Shanghai Yueyang Hospital and normal participants who underwent physical examination in the physical examination center over the same period were retrospectively reviewed. Demographic data, medical history, metabolic disorder indices, and TCM syndrome indices of psoriasis patients and healthy volunteers were evaluated. RESULTS: We included 307 patients with psoriasis and 613 healthy controls. On analyzing past medical history, the proportion of overweight and obesity and the comorbidity of diabetes in the psoriasis group (53.42 and 14.66%) were significantly higher than in the control group (43.88 and 7.67%, respectively; p < .05). The abnormal rates of triglyceride (34.20%), high-density lipoprotein cholesterol (50.49%), and HbA1c (18.57%) levels in the psoriasis group were higher than those in the normal control group (26.75, 17.13, and 12.56%, respectively). Overall, the incidence of metabolic disorders in psoriasis patients (267/307, 86.97%) was higher than that in the normal controls (484/613, 78.96%). Among the different syndrome types, the blood-stasis group had significantly higher rates of hypertension, diabetes, and abnormal glycosylated hemoglobin (46.07, 19.10, and 24.72%, respectively) than those of the control group (27.57, 7.67, and 12.56%; p < .05). Patients with blood stasis syndrome had the highest metabolic disorder comorbidity rate (93.26%) and lowest adiponectin level (p < .05). CONCLUSIONS: TCM syndrome differentiation of psoriasis, especially the diagnosis of blood-stasis syndrome, prompts the early screening of patients with metabolic comorbidities. For patients with psoriasis with metabolic disorder, TCM for promoting blood circulation and removing blood stasis can be compatibly applied without contraindications. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov (Trial ID: NCT03942185).


Subject(s)
Metabolic Diseases , Psoriasis , Humans , Adiponectin , Case-Control Studies , China/epidemiology , Medicine, Chinese Traditional , Metabolic Diseases/complications , Metabolic Diseases/epidemiology , Psoriasis/complications , Psoriasis/epidemiology , Retrospective Studies
4.
Lancet Gastroenterol Hepatol ; 6(9): 743-753, 2021 09.
Article in English | MEDLINE | ID: mdl-34265276

ABSTRACT

With the global epidemics of obesity and associated conditions, including type 2 diabetes, metabolic dysfunction-associated fatty liver disease, chronic kidney disease, hypertension, stroke, cardiovascular disease, osteoporosis, cancer, and cognitive changes, the prevalence of multimorbidity is rapidly increasing worldwide. In this Review, a panel of international experts from across the spectrum of metabolic diseases come together to identify the challenges and provide perspectives on building a framework for a virtual primary care-driven, patient-centred, multidisciplinary model to deliver holistic care for patients with metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. We focus on clinical care and innovative trial design for metabolic dysfunction-associated fatty liver disease and associated metabolic diseases. This work represents a call to action to promote collaboration and partnerships between stakeholders for improving the lives of people with, or at risk of, metabolic dysfunction-associated fatty liver disease and associated metabolic diseases.


Subject(s)
Clinical Trials as Topic/methods , Metabolic Diseases/complications , Non-alcoholic Fatty Liver Disease/therapy , Global Health , Humans , Metabolic Diseases/epidemiology , Metabolic Diseases/therapy , Non-alcoholic Fatty Liver Disease/complications , Non-alcoholic Fatty Liver Disease/epidemiology , Prevalence , Risk Factors
5.
Sci Rep ; 11(1): 4475, 2021 02 24.
Article in English | MEDLINE | ID: mdl-33627680

ABSTRACT

Hypertension in childhood and adolescence is associated with adult cardiovascular morbidity and mortality. However, the reported prevalence of pediatric hypertension varies considerably. We conducted a pioneer nationwide population-based study to investigate the prevalence of hypertension among children and adolescents. Pediatric patients who had been diagnosed with hypertension between 2000 and 2013 were selected from the National Health Insurance Research Database in Taiwan. Other metabolic syndrome-related diseases that would increase cardiovascular risk, including diabetes mellitus (DM), hyperlipidemia, and obesity, were also retrieved for further evaluation. In total, 10,364 children and adolescents diagnosed with hypertension were identified. The prevalence of pediatric hypertension in Taiwan ranged from 0.19 to 0.38 per 1000 children and adolescents between 2000 and 2013. Essential hypertension was most commonly coded (90.6%), which was much more than secondary hypertension (14.3%). Children and adolescents with hypertension were often associated with DM, hyperlipidemia, and obesity, with the odds ratios as 14.05 (95% confidence interval (CI) 11.74-16.81, p < 0.001), 10.65 (95% CI 9.48-11.97, p < 0.001), and 19.08 (95% CI 15.65-23.26, p < 0.001), respectively. To improve lifelong cardiovascular health, our results emphasize the importance of early proper recognition and suitable management of hypertension, as well as metabolic syndrome-related diseases, among children and adolescents.


Subject(s)
Hypertension/epidemiology , Adolescent , Child , Child, Preschool , Databases, Factual , Female , Humans , Hyperlipidemias/epidemiology , Infant , Infant, Newborn , Male , Metabolic Diseases/epidemiology , National Health Programs , Obesity/epidemiology , Odds Ratio , Prevalence , Taiwan/epidemiology
6.
Nutr Hosp ; 38(2): 388-395, 2021 Apr 19.
Article in Spanish | MEDLINE | ID: mdl-33397118

ABSTRACT

INTRODUCTION: Objective: we conducted a systematic review of the main scientific evidence that associates food insecurity with a higher frequency of obesity and cardiometabolic risks in Mexican women. Design: a systematic review. Data sources: MEDLINE, Embase, CINAHL Plus, Web of Science, CAB Abstracts and PAIS Index. Selection criteria: articles that met the journal quality criteria and integrated food status with health insecurity, in which the situation of vulnerability in the current statistics for cardiometabolic diseases and risks that are associated with food insecurity was shown in women and their homes. Data analysis: relevance and quality of the results regarding food security, the presence of overweight and obesity, and socio-environmental indicators in women. Results: households headed by women who are at higher risk of having some degree of food insecurity or food assistance associated with the presence of obesity and overweight (RR = 1.28 to 2.97; 95 % CI: 1.08-1.44 to 1.52-6.14) as well as the development of cardiometabolic diseases such as diabetes mellitus (with a history of pregnancy as risk factor for developing diabetes and hypertension) presenting premature labor, shorter stature in the adult stage, a deficiency in micronutrients such as iron and antioxidant vitamins. Conclusion: the evidence found shows an association of food insecurity as found in women and their homes with a greater risk of being overweight and obese, as well as the development of a cardiometabolic disease (diabetes, hypertension), in addition to anemia and vitamin deficiency.


INTRODUCCIÓN: Objetivo: realizar una revisión de la principal evidencia científica que asocie la inseguridad alimentaria con una mayor frecuencia de obesidad y riesgos cardiometabólicos en mujeres mexicanas. Diseño: revisión sistemática. Fuentes de datos: MEDLINE, Embase, CINAHL Plus, Web of Science, CAB Abstracts y PAIS Index. Selección de estudios: artículos que reunieran los criterios de calidad de las revistas e integraran la situación de inseguridad alimentaria y salud, en los que se viera la situación de vulnerabilidad en las estadísticas actuales de enfermedades y riesgos cardiometabólicos asociados con la situación de inseguridad alimentaria en mujeres y sus hogares. Extracción de datos: relevancia y calidad de los resultados respecto a la seguridad alimentaria, la presencia de sobrepeso y obesidad, e indicadores socioambientales en las mujeres. Resultados: los hogares encabezados por mujeres presentaron mayor riesgo de tener algún grado de inseguridad alimentaria o carencia alimentaria, asociándose esta con la presencia de obesidad y sobrepeso (RR = 1,28 a 2,97; IC 95 %: 1,08-1,44 a 1,52-6,14) así como con el desarrollo de enfermedades cardiometabólicas como la diabetes mellitus (siendo el embarazo, como antecedente, un factor de riesgo para desarrollar diabetes e hipertensión), presentar partos prematuros, tener menor estatura en la etapa adulta, una deficiencia de micronutrimentos como el hierro y de vitaminas antioxidantes. Conclusiones: la evidencia encontrada muestra una asociación de la inseguridad alimentaria encontrada en las mujeres y sus hogares con una mayor probabilidad de presentar sobrepeso y obesidad, así como el desarrollo de una enfermedad de índole cardiometabólica (diabetes, hipertensión), además de anemia y deficiencia de vitaminas.


Subject(s)
Cardiovascular Diseases/epidemiology , Family Characteristics , Food Insecurity , Metabolic Diseases/epidemiology , Obesity/epidemiology , Adolescent , Adult , Anemia/epidemiology , Avitaminosis/epidemiology , Diabetes Mellitus/epidemiology , Female , Food Assistance , Humans , Hypertension/epidemiology , Mexico/epidemiology , Overweight/epidemiology , Pregnancy , Pregnancy Complications/epidemiology , Premature Birth/epidemiology , Prevalence , Public Policy , Risk Factors , Young Adult
7.
Syst Rev ; 9(1): 274, 2020 12 01.
Article in English | MEDLINE | ID: mdl-33261659

ABSTRACT

BACKGROUND: Recent systematic review of clinical trials concluded that there was no convincing evidence to suggest an association between potatoes and risk of cardio-metabolic diseases. OBJECTIVE: Summarize observational study data related to potato intake and cardio-metabolic health outcomes in adults using evidence mapping to assess the need for a future systematic review. METHODS: We searched MEDLINE®, Commonwealth Agricultural Bureau, and bibliographies for eligible observational studies published between 1946 and July 2020. Included studies evaluated potato intake in any form or as part of a dietary pattern with risk for cardio-metabolic diseases. Outcomes of interest included cardiovascular disease (CVD), cerebrovascular diseases, diabetes, hypertension, blood lipids, and body composition. RESULTS: Of 121 eligible studies, 51 reported two different methods to quantify potato intake (30 studies quantified intake as either grams or serving; 20 studies reported times per week; one reported both methods) and 70 reported potato as part of a dietary pattern and compared higher vs. lower intake, linear change, or difference in potato intake among cases and controls. Studies that quantified potato intake as either grams or serving reported the following outcomes: diabetes (8 studies); cerebrovascular stroke (6 studies); five studies each for CVD, systolic and diastolic blood pressure, and hypertension; three studies each for body mass index, body weight, CVD mortality; two studies for myocardial infarction; and one study each for blood glucose, HOMA-IR, and blood lipids. Higher potato intake was associated with an increased risk for blood pressure and body weight, and the results of all other outcomes observed no association. Potato consumption as part of dietary pattern studies reported a negative association between fried form of potato and all or most cardio-metabolic risk factors and diseases. CONCLUSION: Evidence mapping found sufficient data on the association between potato intake and cardio-metabolic disease risk factors to warrant for a systematic review/meta-analysis of observational studies.


Subject(s)
Cardiovascular Diseases , Metabolic Diseases , Solanum tuberosum , Adult , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/etiology , Diet , Humans , Metabolic Diseases/epidemiology , Observational Studies as Topic , Risk Factors
8.
Phytother Res ; 34(12): 3113-3123, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32614129

ABSTRACT

Recent evidence indicates a beneficial effect of Melissa officinalis (MO) intake on several chronic diseases. However, the effects of MO intake have not yet been systematically reviewed. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the effect of MO intake and focused on several cardiometabolic outcomes. MEDLINE, Scopus, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials were searched for MO-RCTs evaluating cardiometabolic outcomes. Random-effects meta-analyses estimated the pooled standardized mean differences (SMD) between intervention and control groups. Risk of bias was assessed with the Cochrane Collaboration's tool for assessing the risk of bias in RCTs. Seven RCTs were finally deemed eligible. MO intake was associated with a reduced total cholesterol (TC) (SMD: -0.26; 95% CI: -0.52, -0.01; I2 = 13.7%; k = 6) and a reduced systolic blood pressure (SBP) (SMD: -0.56; 95% CI: -0.85, -0.27; I2 = 00.0%; k = 3). MO intake was not associated with statistically significant changes in triglycerides, low-density lipoprotein, diastolic blood pressure, high sensitivity c-reactive protein levels, fasting blood sugar, HbA1c, insulin or high-density lipoprotein levels. No serious adverse events were reported. The risk of bias was high in a considerable amount of studies. Our study suggests that MO is a safe supplement with beneficial effects on TC and SBP. However, the findings of our study must be seen in the light of major limitations such as a low number of included studies and a serious risk of bias. High-quality RCTs are needed for firm conclusions concerning the effects of MO on cardiometabolic outcomes.


Subject(s)
Cardiovascular Diseases/drug therapy , Melissa/chemistry , Metabolic Diseases/drug therapy , Plant Extracts/therapeutic use , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Chronic Disease , Dietary Supplements , Humans , Melissa/physiology , Metabolic Diseases/diagnosis , Metabolic Diseases/epidemiology , Phytotherapy , Plant Extracts/pharmacology , Randomized Controlled Trials as Topic/statistics & numerical data , Treatment Outcome
9.
Article in English | MEDLINE | ID: mdl-32296394

ABSTRACT

Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women at reproductive age, which is characterized by obesity, hyperandrogenemia, and insulin resistance (IR). This study aimed to investigate the vitamin D status, and analyze the relationship between vitamin D deficiency and metabolic risk factors in PCOS women in Shaanxi China. Methods: A cross-sectional study included 169 women diagnosed with PCOS and 114 control women without PCOS. The serum 25(OH)D and metabolic markers were measured. Vitamin D deficiency was defined as serum 25(OH)D concentration less than 20 ng/mL. The primary outcome was the difference in vitamin D status between the PCOS and control groups, the secondary outcomes were correlations between serum 25(OH)D concentration and metabolic risk factors in women with PCOS. Results: The serum 25(OH)D concentration was significantly lower in women with PCOS than in controls (P < 0.05), and the prevalence rates of 25(OH)D deficiency and insufficiency were significantly higher in women with PCOS than in controls (P < 0.05). The serum 25(OH)D concentration was significantly lower in PCOS women with obesity or IR than in women without obesity or IR (P < 0.05), and the prevalence of 25(OH)D deficiency in PCOS women with obesity or IR was significantly higher than in women without obesity or IR (P < 0.05). Serum 25(OH)D concentration was significantly negatively correlated with body mass index (BMI), waist-to-hip ratio (WHR), fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-sensitivity C-reactive protein (hs-CRP) (P < 0.05). In comparison, serum 25(OH)D concentration was significantly positively correlated with high-density lipoprotein cholesterol (HDL-C) (P < 0.05). Increased BMI and WHR, high levels of fasting insulin, HOMA-IR, total cholesterol, LDL-C and hs-CRP were regarded as risk factors, but high level of HDL-C was considered to be protective factor of vitamin D deficiency in PCOS women. Conclusions: Vitamin D deficiency is prevalent in PCOS women in Shaanxi China, especially in those with obesity and IR. The serum 25(OH)D level was correlated with metabolic risk factors in PCOS women. Multi-center randomized controlled trials with large sample sizes are needed to probe the metabolic effect of vitamin D supplementation in PCOS women.


Subject(s)
Metabolic Diseases/etiology , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/epidemiology , Vitamin D Deficiency/complications , Vitamin D Deficiency/epidemiology , Adult , Body Mass Index , Cardiometabolic Risk Factors , Case-Control Studies , China/epidemiology , Cross-Sectional Studies , Female , Humans , Insulin Resistance/physiology , Metabolic Diseases/blood , Metabolic Diseases/epidemiology , Obesity/complications , Obesity/epidemiology , Obesity/metabolism , Polycystic Ovary Syndrome/metabolism , Prevalence , Risk Factors , Vitamin D/blood , Vitamin D Deficiency/metabolism , Young Adult
10.
BMC Cancer ; 20(1): 310, 2020 Apr 15.
Article in English | MEDLINE | ID: mdl-32293339

ABSTRACT

BACKGROUND: Cancer development is mediated by oxidative stress and inflammation, which may correlate with metabolic disorders. The aim of this study was to evaluate antioxidant vitamins status and metabolic parameters in patients with oral cancer according to tumor-node-metastasis (TNM) stages. METHODS: A total of 194 patients with oral cancer were enrolled in this study. The patients were stratified for four groups according to cancer stages and that the statistics are comparisons across these groups. The levels of antioxidant vitamins (ubiquinone, ß-carotene, vitamin A and E), metabolic parameters, oxidative stress, antioxidant enzymes activity, and inflammatory markers were measured. RESULTS: More than half of the subjects had high blood pressure, central obesity, hyperglycemia, and hyperlipidemia regardless of TNM stage. With regard to antioxidant vitamins status, 46 and 94% of patients had ß-carotene and ubiquinone deficiency, respectively. Patients in T3 and T4 stages had significantly lower antioxidant enzyme (catalase, p = 0.03) activity and higher inflammatory markers levels (high sensitivity C-reactive protein and interleukin-6, p < 0.01) than patients in the other stages. In addition, the level of ß-carotene was negatively associated with waist circumference, and ubiquinone was positively associated with the level of high-density lipoprotein cholesterol (p < 0.05). Higher ß-carotene and ubiquinone levels were negatively associated with hypertriglyceridemia and the risk of metabolic syndrome (p < 0.05). CONCLUSIONS: A high proportion of patients with oral cancer had ubiquinone or ß-carotene deficiency and metabolic disorders. The level of ubiquinone or ß-carotene was negatively associated with the risk of central obesity, hypertriglyceridemia, and metabolic syndrome. Since patients with oral cancer suffer from high oxidative stress and inflammation (particularly in the T3 and T4 stages), supplementation with antioxidant vitamins such as ubiquinone or ß-carotene could be preferentially applied.


Subject(s)
Metabolic Diseases/epidemiology , Mouth Neoplasms/pathology , Ubiquinone/deficiency , beta Carotene/deficiency , Adult , Aged , C-Reactive Protein/metabolism , Cross-Sectional Studies , Female , Humans , Interleukin-6/blood , Male , Metabolic Diseases/blood , Metabolic Diseases/classification , Middle Aged , Mouth Neoplasms/blood , Neoplasm Staging , Oxidative Stress , Vitamin A/blood , Vitamin E/blood
11.
Metabolism ; 103S: 154049, 2020 02.
Article in English | MEDLINE | ID: mdl-31863781

ABSTRACT

X-linked hypophosphatemia (XLH) is caused by mutations in the PHEX gene which result in Fibroblast Growth Factor-23 (FG-F23) excess and phosphate wasting. Clinically, XLH children present with rickets, bone deformities and short stature. In adulthood, patients may still be symptomatic with bone and joint pain, osteomalacia-related fractures or pseudofractures, precocious osteoarthrosis, enthesopathy, muscle weakness and severe dental anomalies. Besides these musculoskeletal and dental manifestations, adult XLH patients are also prone to secondary and tertiary hyperparathyroidism, cardiovascular and metabolic disorders. Pathophysiology of hyperparathyroidism is only partially understood but FGF23 excess and deficient production of calcitriol likely contributes to its development. Similarly, the pathophysiological mechanisms of potential cardiovascular and metabolic involvements are not clear, but FGF-23 excess may play an essential role. Treatment should be considered in symptomatic patients, patients undergoing orthopedic or dental surgery and women during pregnancy and lactation. Treatment with oral phosphate salts and active vitamin D analogs has incomplete efficacy and potential risks. Burosumab, a recombinant human monoclonal antibody against FGF-23, has proven its efficacy in phase 2 and phase 3 clinical trials in adult patients with XLH, but currently its position as first line or second line treatment differ among the countries.


Subject(s)
Familial Hypophosphatemic Rickets/therapy , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Cardiovascular Diseases/epidemiology , Endocrine System Diseases/epidemiology , Familial Hypophosphatemic Rickets/complications , Female , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/antagonists & inhibitors , Fibroblast Growth Factors/physiology , Humans , Hyperparathyroidism/prevention & control , Metabolic Diseases/epidemiology , Mutation , PHEX Phosphate Regulating Neutral Endopeptidase/genetics , Phosphates/therapeutic use , Pregnancy , Vitamin D/therapeutic use
12.
Nutrients ; 11(9)2019 Sep 13.
Article in English | MEDLINE | ID: mdl-31540227

ABSTRACT

The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) conducted a review of existing systematic reviews and meta-analyses to explain the relationship between different dietary patterns and patient-important cardiometabolic outcomes. To update the clinical practice guidelines for nutrition therapy in the prevention and management of diabetes, we summarize the evidence from these evidence syntheses for the Mediterranean, Dietary Approaches to Stop Hypertension (DASH), Portfolio, Nordic, liquid meal replacement, and vegetarian dietary patterns. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the quality of evidence. We summarized the evidence for disease incidence outcomes and risk factor outcomes using risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs), respectively. The Mediterranean diet showed a cardiovascular disease (CVD) incidence (RR: 0.62; 95%CI, 0.50, 0.78), and non-significant CVD mortality (RR: 0.67; 95%CI, 0.45, 1.00) benefit. The DASH dietary pattern improved cardiometabolic risk factors (P < 0.05) and was associated with the decreased incidence of CVD (RR, 0.80; 95%CI, 0.76, 0.85). Vegetarian dietary patterns were associated with improved cardiometabolic risk factors (P < 0.05) and the reduced incidence (0.72; 95%CI: 0.61, 0.85) and mortality (RR, 0.78; 95%CI, 0.69, 0.88) of coronary heart disease. The Portfolio dietary pattern improved cardiometabolic risk factors and reduced estimated 10-year coronary heart disease (CHD) risk by 13% (-1.34% (95%CI, -2.19 to -0.49)). The Nordic dietary pattern was correlated with decreased CVD (0.93 (95%CI, 0.88, 0.99)) and stroke incidence (0.87 (95%CI, 0.77, 0.97)) and, along with liquid meal replacements, improved cardiometabolic risk factors (P < 0.05). The evidence was assessed as low to moderate certainty for most dietary patterns and outcome pairs. Current evidence suggests that the Mediterranean, DASH, Portfolio, Nordic, liquid meal replacement and vegetarian dietary patterns have cardiometabolic advantages in populations inclusive of diabetes.


Subject(s)
Diabetes Mellitus/diet therapy , Diet , Nutrition Therapy/methods , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Cardiovascular Diseases/prevention & control , Diabetes Complications/epidemiology , Diabetes Complications/prevention & control , Diet, Mediterranean , Diet, Vegetarian , Dietary Approaches To Stop Hypertension , Humans , MEDLINE , Meta-Analysis as Topic , Metabolic Diseases/epidemiology , Metabolic Diseases/prevention & control , Risk Factors , Scandinavian and Nordic Countries , Systematic Reviews as Topic
13.
Dtsch Med Wochenschr ; 144(17): 1212-1217, 2019 08.
Article in German | MEDLINE | ID: mdl-31454844

ABSTRACT

The prevalence of dementias is on the rise, increases exponentially with age and constitutes a major healthcare burden nationally and worldwide. Dementias are clinically heterogeneous and encompass numerous etiologies. Noteworthy, late onset dementias are closely related to vascular and metabolic risk factors in midlife. Cardiometabolic risk factors commonly precede the onset of cognitive decline for decades. This opens a huge window for prevention. Given the lack of established pharmacological options for treatment of most dementias, preventive strategies are of utmost importance. Several factors have been identified that have the potential to preserve a healthy metabolic phenotype and to attenuate the onset of late onset dementias. Evidence exists for low-risk lifestyle factors including a real food dietary pattern, an adequate supply with long chain omega-3 fatty acids, regular physical activity and restorative sleep, with multimodal concepts showing the greatest cumulative benefit.


Subject(s)
Cardiovascular Diseases , Dementia , Metabolic Diseases , Risk Reduction Behavior , Blood Glucose , Cardiovascular Diseases/complications , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Dementia/complications , Dementia/epidemiology , Dementia/prevention & control , Diet , Humans , Insulin Resistance , Metabolic Diseases/complications , Metabolic Diseases/epidemiology , Metabolic Diseases/prevention & control , Risk Factors
14.
Nutrients ; 11(8)2019 Aug 05.
Article in English | MEDLINE | ID: mdl-31387247

ABSTRACT

Plant-based diets rich in bioactive compounds such as polyphenols have been shown to positively modulate the risk of cardiometabolic (CM) diseases. The inter-individual variability in the response to these bioactives may affect the findings. This systematic review aimed to summarize findings from existing randomized clinical trials (RCTs) evaluating the effect of hydroxycinnamic acids (HCAs) on markers of CM health in humans. Literature searches were performed in PubMed and the Web of Science. RCTs on acute and chronic supplementation of HCA-rich foods/extracts on CM biomarkers were included. Forty-four RCTs (21 acute and 23 chronic) met inclusion criteria. Comparisons were made between RCTs, including assessments based on population health status. Of the 44 RCTs, only seven performed analyses on a factor exploring inter-individual response to HCA consumption. Results demonstrated that health status is a potentially important effect modifier as RCTs with higher baseline cholesterol, blood pressure and glycaemia demonstrated greater overall effectiveness, which was also found in studies where specific subgroup analyses were performed. Thus, the effect of HCAs on CM risk factors may be greater in individuals at higher CM risk, although future studies in these populations are needed, including those on other potential determinants of inter-individual variability. PROSPERO, registration number CRD42016050790.


Subject(s)
Biological Variation, Individual , Cardiovascular Diseases/prevention & control , Coumaric Acids/administration & dosage , Diet , Dietary Supplements , Metabolic Diseases/prevention & control , Adult , Aged , Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/physiopathology , Coumaric Acids/adverse effects , Diet/adverse effects , Dietary Supplements/adverse effects , Female , Humans , Male , Metabolic Diseases/blood , Metabolic Diseases/epidemiology , Metabolic Diseases/physiopathology , Middle Aged , Nutritional Status , Nutritive Value , Protective Factors , Randomized Controlled Trials as Topic , Risk Factors , Risk Reduction Behavior , Young Adult
15.
Neurobiol Dis ; 132: 104544, 2019 12.
Article in English | MEDLINE | ID: mdl-31351171

ABSTRACT

Metabolic interventions including special diets and supplements are commonly used in Autism Spectrum Disorder (ASD). Yet little is known about how these interventions, typically initiated by caregivers, may affect metabolic function or the core symptoms of ASD. This review examines possible direct and indirect roles for metabolism in the core symptoms of ASD as well as evidence for metabolic dysfunction and nutritional deficiencies. We also discuss some of the most popular diets and supplements used in our patient population and suggest strategies for discussing the utility of these interventions with patients, families, and caregivers.


Subject(s)
Autism Spectrum Disorder/diet therapy , Autism Spectrum Disorder/metabolism , Nutritional Status/physiology , Nutritional Support/methods , Autism Spectrum Disorder/epidemiology , Diet, Gluten-Free/methods , Diet, Gluten-Free/trends , Diet, Ketogenic/methods , Diet, Ketogenic/trends , Dietary Supplements , Humans , Metabolic Diseases/diet therapy , Metabolic Diseases/epidemiology , Metabolic Diseases/metabolism , Nutritional Support/trends , Vitamins/administration & dosage
16.
Libyan J Med ; 14(1): 1622364, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31146648

ABSTRACT

Libyan women are at high risk of vitamin D deficiency, mostly due to their lifestyle and low exposure to sun. In the last decades, Libyan residents have been forced to seek refuge in countries such as Serbia, a country with high incidence of cardio-metabolic diseases. Serbian residents tend to be deficient in vitamin D, mostly due to the lack of vitamin D fortification policy. The aim of this study was to evaluate vitamin D status in Libyan adult women migrating to Serbia, with the assessment of cardio-metabolic and nutritional biomarkers, including erythrocytes fatty acid composition, magnesium concentration, and dietary intake. The same markers were measured in Serbian women, and comparisons between the groups were made. Despite low vitamin D dietary intake in both study groups, we observed lower plasma vitamin D status in Libyan women. This was accompanied by a significantly lower concentration of magnesium in Libyan women. Libyan women had significantly higher omega-3 index and lower n-6/n-3 ratio in erythrocytes' phospholipids. We observed significant negative correlation between vitamin D and n-6 polyunsaturated fatty acids (PUFA) concentrations in both study groups. Despite lower vitamin D status in the Libyan group, erythrocyte fatty acid composition, along with blood lipids' concentrations, indicated a lower cardiovascular risk. Based on our results, the discrepancy in the vitamin D status could not be ascribed to the participants' dietary intake of the micronutrient, rather is potentially associated with ethnic-specific cardio-metabolic profile, which should be confirmed in larger cohorts.


Subject(s)
Biomarkers/blood , Erythrocytes/metabolism , Recommended Dietary Allowances/trends , Vitamin D Deficiency/complications , Vitamin D/blood , Adult , Cardiovascular Diseases/epidemiology , Cross-Sectional Studies , Fatty Acids, Omega-3/blood , Fatty Acids, Omega-6/blood , Female , Humans , Incidence , Libya/epidemiology , Life Style , Magnesium/blood , Metabolic Diseases/epidemiology , Middle Aged , Serbia/epidemiology , Sunlight/adverse effects , Transients and Migrants , Vitamin D Deficiency/epidemiology
17.
Int J Mol Sci ; 20(2)2019 Jan 14.
Article in English | MEDLINE | ID: mdl-30646503

ABSTRACT

Many populations use medicinal plants as a therapeutic treatment, due to their lower cost and greater access. Among the plant species used for medicinal purposes are those of the genus Morus. The most known species are Morus alba, rubra, and nigra. This review aims to collect data from the literature, predominantly from cell and animal studies, which presents a possible nutraceutical and medicinal potential of the species Morus for use in metabolic dysfunctions. The fruits and leaves of mulberry are used for therapeutic purposes. For scientific confirmation of these effects, they were studied for laxative properties, antibacterial activity, anti-atherogenic activity, and hepatoprotective function. Furthermore, the genus Morus is recognized for the treatment and prevention of diabetes mellitus, through its hypoglycemic action. It may also provide health benefits through immunomodulatory, anti-inflammatory, and anti-nociceptive effects. It has been found that the Morus species have phenolic compounds, flavonoids, and anthocyanins that act as important antioxidants and promote beneficial effects on human health. These phytochemical compounds differ among species. Blackberry (Morus nigra) are rich in flavonoids, while the white mulberry (Morus alba) has low concentrations of flavonoids and anthocyanins. In addition, another important factor is to ensure a complete exemption of toxic risks in the use of medicinal plants for the treatment of diseases. Studies have shown no toxic effects by the administration of extracts of Morus species. Thus, the mulberry tree presents nutraceutical potential. It is therefore a promising alternative for medicinal products based on medicinal plants.


Subject(s)
Metabolic Diseases/drug therapy , Morus/chemistry , Plant Extracts/therapeutic use , Plants, Medicinal/chemistry , Dietary Supplements , Fruit/chemistry , Humans , Metabolic Diseases/epidemiology , Phenols/chemistry , Phenols/therapeutic use , Phytochemicals/chemistry , Phytochemicals/therapeutic use , Plant Extracts/chemistry , Plant Leaves/chemistry
18.
Article in English | MEDLINE | ID: mdl-29968548

ABSTRACT

BACKGROUND: Multiple cross sectional and longitudinal studies reported the benefits of vitamin K intake for management of cardiometabolic risk factors so as to minimize the risk of cardiovascular diseases. OBJECTIVE: In present systematic review and meta-analysis, we aimed to evaluate the effect of vitamin K supplementation on cardiometabolic risk factors. METHODOLOGY: A systematic literature search of PubMed, Cochrane central, Clinicaltrials.gov, Google Scholar, Web of Science, EBSCO and Scopus databases was done from inception to November, 2017. A total of 13 trials were selected for inclusion into the present systematic review to evaluate the effect of vitamin K supplementation on cardiometabolic risk factors in healthy or in population at high risk of cardiovascular diseases. RESULTS: Significant beneficial effects of vitamin K supplementation were found only in case of Creactive protein (p = 0.01) and insulin sensitivity index (p <0.001), while no significant effects of vitamin K supplementation were found in case of total cholesterol (p=0.857), low density lipoprotein - cholesterol (p=0.964), high density lipoprotein - cholesterol (p=0.998), interleukin - 6 (p=0.766), systolic blood pressure (p=0.660), diastolic blood pressure (p=0.818), fasting plasma glucose (p=0.362), fasting plasma insulin (p=0.928) and homeostasis model assessment for insulin resistance (p=0.672). CONCLUSION: Presently available evidence are insufficient to ascertain the beneficial effects of vitamin K supplementation for the management of cardiometabolic risk factors. In order to explore the true potential of vitamin K supplementation for management of cardiometabolic diseases, large randomized placebo controlled trials are required in population with disturbed cardiometabolic profile. Present systematic review and meta-analysis is registered with PROSPERO (Registration number: CRD42018084608).


Subject(s)
Cardiovascular Diseases/prevention & control , Dietary Supplements , Metabolic Diseases/prevention & control , Vitamin K/therapeutic use , Vitamins/therapeutic use , Cardiovascular Diseases/epidemiology , Humans , Metabolic Diseases/epidemiology , Risk Factors , Vitamin K/adverse effects , Vitamins/adverse effects
19.
Nutrients ; 10(10)2018 Sep 30.
Article in English | MEDLINE | ID: mdl-30274325

ABSTRACT

The role of dietary fat has been long studied as a modifiable variable in the prevention and treatment of noncommunicable cardiometabolic disease. Once heavily promoted to the public, the low-fat diet has been demonstrated to be non-effective in preventing cardiometabolic disease, and an increasing body of literature has focused on the effects of a relatively higher-fat diet. More recent evidence suggests that a diet high in healthy fat, rich in unsaturated fatty acids, such as the Mediterranean dietary pattern, may, in fact, prevent the development of metabolic diseases such as type 2 diabetes mellitus, but also reduce cardiovascular events. This review will specifically focus on clinical trials which collected data on dietary fatty acid intake, and the association of these fatty acids over time with measured cardiometabolic health outcomes, specifically focusing on morbidity and mortality outcomes. We will also describe mechanistic studies investigating the role of dietary fatty acids on cardiovascular risk factors to describe the potential mechanisms of action through which unsaturated fatty acids may exert their beneficial effects. The state of current knowledge on the associations between dietary fatty acids and cardiometabolic morbidity and mortality outcomes will be summarized and directions for future work will be discussed.


Subject(s)
Dietary Fats/administration & dosage , Noncommunicable Diseases/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/mortality , Clinical Trials as Topic , Diabetes Mellitus, Type 2/epidemiology , Diet, Fat-Restricted , Diet, High-Fat , Diet, Mediterranean , Fatty Acids/administration & dosage , Humans , Metabolic Diseases/epidemiology , Metabolic Diseases/mortality , Risk Factors , Women's Health
20.
Int J Dermatol ; 57(9): 1068-1074, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29978903

ABSTRACT

BACKGROUND: Updated data regarding the epidemiology of psoriasis and related healthcare utilization are lacking. OBJECTIVE: To investigate the epidemiology, comorbidities, healthcare services utilization, and drug use in a large group of patients with psoriasis from Clalit Health Services (CHS) database. METHODS: A controlled cross-sectional study was performed. Case patients were defined when there was at least one documented diagnosis of psoriasis registered by a CHS dermatologist between the years 1998-2016. The extracted data included metabolic, cardiovascular and psychiatric comorbidities; community clinic visits; in- and outpatient services utilization profiles and drug use data, which included pharmacy claims of topical and systemic treatments, including phototherapy and climatotherapy. Comparative analysis was performed by a univariate and multivariate analysis, adjusting for age, gender, obesity, and smoking. RESULTS: The study included 118,680 patients with psoriasis (prevalence of 2.69%) and 118,680 age- and gender-matched controls. Patients with psoriasis had increased prevalence of metabolic, cardiovascular, and psychiatric illnesses. Psoriasis was significantly associated with an increased healthcare utilization. The mean (SD) number of annual dermatologist clinic visits and emergency room visits was 7.2 ± 12.4 and 2.9 ± 7.7 in psoriasis patients as compared to 2.9 ± 7.9 and 2.7 ± 7.4 in the control group (P < 0.001). Topical steroids were the most applied treatment in psoriasis patients (15.5%), and topical vitamin D analogs were second in use (14.6%). Traditional systemic treatment for psoriasis was used in 3.8% of the patients, and biologic treatments were used in 1.6% of the patients. CONCLUSIONS: Our study quantifies healthcare services utilization and drug use in patients with psoriasis.


Subject(s)
Cardiovascular Diseases/epidemiology , Dermatology/statistics & numerical data , Emergency Service, Hospital/statistics & numerical data , Mental Disorders/epidemiology , Metabolic Diseases/epidemiology , Psoriasis/epidemiology , Comorbidity , Cross-Sectional Studies , Female , Humans , Israel/epidemiology , Male , Middle Aged , Prevalence , Psoriasis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL